ImmuCell Corp.

How big is ImmuCell Corp.?

As of Jun 18, ImmuCell Corp. has a market capitalization of 57.57 million, categorizing it as a Micro Cap company, with net sales of 27.30 million and a net profit of -0.26 million over the latest four quarters.

Market Cap: As of Jun 18, ImmuCell Corp. has a market capitalization of 57.57 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, ImmuCell Corp. reported net sales of 27.30 million and a net profit of -0.26 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 27.52 million and total assets of 45.10 million.

What does ImmuCell Corp. do?

ImmuCell Corp. is an animal health company focused on developing products to enhance the health and productivity of dairy and beef cattle. As of March 2025, it reported net sales of $8 million and a net profit of $1 million, with a market cap of $57.57 million.

Overview:<BR>ImmuCell Corp. is an animal health company that develops, manufactures, and sells products aimed at improving the health and productivity of cows in the dairy and beef industries, operating within the Pharmaceuticals & Biotechnology sector.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 8 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 57.57 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 0.21 <BR>Return on Equity: -0.94% <BR>Price to Book: 1.99 <BR><BR>Contact Details:<BR>Address: 56 Evergreen Dr, PORTLAND ME: 04103-1066 <BR>Tel: 1 207 8782770 <BR>Website: http://www.immucell.com/

Should I buy, sell or hold ImmuCell Corp.?

Who are in the management team of ImmuCell Corp.?

As of March 2022, ImmuCell Corp.'s management team includes Dr. David Tomsche (Chairman), Mr. Michael Brigham (President and CEO), Ms. Bobbi Brockmann (VP of Sales and Marketing), and several Independent Directors: Mr. David Cunningham, Mr. Steven Rosgen, Mr. Jonathan Rothschild, and Mr. Paul Wainman. This team oversees the company's operations and strategic direction.

As of March 2022, the management team of ImmuCell Corp. includes the following individuals:<BR><BR>- Dr. David Tomsche, who serves as the Chairman of the Board.<BR>- Mr. Michael Brigham, who holds multiple roles as President, Chief Executive Officer, Treasurer, Secretary, and Director.<BR>- Ms. Bobbi Brockmann, who is the Vice President of Sales and Marketing and also a Director.<BR>- Additionally, the board includes several Independent Directors: Mr. David Cunningham, Mr. Steven Rosgen, Mr. Jonathan Rothschild, and Mr. Paul Wainman. <BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Is ImmuCell Corp. technically bullish or bearish?

As of September 4, 2025, ImmuCell Corp. shows a mildly bullish trend overall, despite mixed signals from technical indicators and recent underperformance compared to the S&P 500.

As of 4 September 2025, the technical trend for ImmuCell Corp. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals across time frames. The daily moving averages are mildly bullish, suggesting some short-term support. However, the weekly Bollinger Bands are bearish, which adds to the caution. The stock has underperformed the S&P 500 over the past week and month, with returns of -7.67% and -7.36% respectively, while it has outperformed over the past year with a return of 57.22% compared to the S&P 500's 17.14%. Overall, the current stance is mildly bullish, but with significant caution due to mixed indicators.

Is ImmuCell Corp. overvalued or undervalued?

As of October 17, 2025, ImmuCell Corp. is considered overvalued with a valuation grade shift from attractive to expensive, highlighted by high Price to Book and EV to EBITDA ratios, negative return metrics, and a premium P/E ratio compared to peers, despite recent strong performance relative to the S&P 500.

As of 17 October 2025, the valuation grade for ImmuCell Corp. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 2.05 and an EV to EBITDA ratio of 26.30, which are significantly higher than typical industry benchmarks. Additionally, the company has a negative ROCE of -0.63% and ROE of -0.94%, suggesting inefficiencies in generating returns.<BR><BR>In comparison to its peers, ImmuCell Corp. has a notably high P/E ratio of 33.88, while ImmunoPrecise Antibodies Ltd. shows a negative P/E of -13.04, and Rani Therapeutics Holdings, Inc. also reflects a negative P/E of -0.74, indicating that ImmuCell is trading at a premium despite its losses. Over the past year, ImmuCell has outperformed the S&P 500 with a return of 67.17% compared to the index's 14.08%, but its long-term performance over three and five years has lagged significantly behind the S&P 500, which raises concerns about sustainability.